Quidel secures Health Canada approval for Sofia SARS-CoV-2 test

By LabPulse.com staff writers

May 25, 2021 -- Health Canada has approved Quidel's Sofia antigen test for the detection of coronavirus infection in both symptomatic and asymptomatic people.

The nasal swab test is used with Quidel's Sofia and Sofia 2 test instruments. The Sofia Severe Acute Respiratory Syndrome (SARS) Antigen Fluorescence Immunoassay (FIA) test has been shown to perform well within the first five days of symptom onset; positive results agree with reverse transcription polymerase chain reaction (RT-PCR) tests 96.7% of the time and negative results agree 100% of the time, according to the firm.

Boom in COVID testing drives Quidel's Q1 financials
Quidel on April 22 announced preliminary numbers for the first quarter of 2021 that saw revenue from the company's line of COVID-19 tests boom to $280 million...
Quidel nabs EUA from FDA for SARS-CoV-2 antigen test
Quidel has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QuickVue point-of-care assay that detects...
Quidel gets EUA for combo flu, COVID-19 test
Quidel has received a U.S. Food and Drug Administration emergency use authorization (EUA) for a rapid diagnostic that can simultaneously identify influenza...
Quidel closes Vermont investigation of Sofia test
Quidel has completed its investigation of false-positive results for COVID-19 at a testing location in Vermont. The company said it found no testing site-...
Quidel updates performance data for Sofia antigen test
Quidel has updated performance data for its Sofia immunoassay test to reflect further studies it conducted as part of its emergency use authorization...

Copyright © 2021 LabPulse.com

Last Updated ls 5/25/2021 2:59:03 PM